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ABSTRACT 
Since the 1980s cancer is the leading cause 
of death in Japan. Most human cancers exhibit inactivation of the p53 network, either through 
direct mutation of p53,or through disruption of 
regulatory pathways essential for p53 function. 
The tumor suppressor gene p53 encodes a tran- 
scriptional activator as a nodal point for cellular 
responses to several stress conditions. p53 is one 
of the most highly connected nodes in the cell, 
and an attack on p53 by mutation wil disrupt 
INTRODUCTION
The tumor suppressor gene p53 encodes a 
transcriptional activator as a nodal point for cel- 
lular responses to DNA damages, oncogenic 
stress and celular stress conditions. The major- ity of cancer-associated mutations in p53 are 
missense mutations in its DNA-binding domain'). 
These mutations usualy lead to the formation 
of a ful-length mutant protein(mutant p53) in- capable of transactivating p53 target genes and 
suppressing tumorigenesis. Besides the loss of 
wild-type activity, many p53 mutants also func- 
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basic cellular functions, particularly responses to 
DNA damage and tumor-predisposing stresses. 
p63 and p73 are functionally and structurally re- 
lated to the tumor suppressor p53. Recent find- 
ings from others and us have provided evidence 
for a broader role for the p53 family than were 
previously reported. In this review, we provide 
an overview of the networks controlled by the 
p53 family as a framework for developing p53 family-based strategies to treat cancer. 
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tion as dominant-negative proteins that inacti- 
vate wild-type p53 expressed from the remain- 
ing wild-type allele. Some data indicate that 
mutant p53 proteins not only lose tumor sup- 
pressive functions, but also gain new abilities 
that promote tumorigenesis. Although still con- 
troversial, the presence of mutant p53 in cancer 
cels is associated with more aggressive tumors and correspondingly worse outcomes. The 
means by which mutant p53 exerts such pro- 
oncogenic activity are currently under exten- 
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sive investigation and different models have 
been proposed. A subset of tumor-derived p53 
mutants is proposed to physicaly interact with 
p53 family members, p63 and p73, and nega- 
tively regulate their proapoptotic function2). As half of human tumors harbor mutant forms of 
p53 protein, approaches aimed at disrupting the 
pathological interactions among p53 family 
members might be clinicaly useful. 
The p53 gene family consists of three 
members p53, p63 and p73 that are homolo- 
gous in three domains: the N-terminal transcrip- 
tional activation domain (TA), the central core 
sequence-specific DNA-binding domain (DB) and the C-terminal located oligomerization do-
main(0L) (Fig.1). p63 and p73, which generaly share more homology with each other than with 
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p53, can be expressed as two N-terminal iso- 
forms that either contain(TA)or lack(△N) a full TA domain through alternate promoter usage 
(Figure 1). These two isoforms in turn can each have different C-termini as a result of alterna- 
tive splicing. In general, the ful-length TA ver- 
sions of p63/p73 can exert p53-like activities, 
whereas the△N versions have an opposite ef- 
fect3). 
At least three and seven C-terminal iso- 
forms have been identified for p63 and p73, re- 
spectively4,5). These distinct C-termini are 
thought to modulate the ability of the respective 
TA isoforms to transactivate target gene ex- 
pression. The TAP63αand TAP73αisoforms 
are the largest proteins in each family. The 
TAP63γand TAP73γisoforms most closely re- 
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Fjgure l Structures of p53 and p63 major isoforms. The p53 family protein consists of three separable and func-
tjona1y essential domains: an N-terminal transcriptional activation domain(TA), a central core sequence-specific DNA-binding domain(DB) and a C-terminal located oligomerization domain(0L). The regula-tjon of transcriptional activity is quite different between p53 and p63. The amount of p53 protein in nor-mal cels is determined mainly by the rate at which it is degraded. The degradation proceeds through 
ubiquitin-mediated proteolysis. The MDM2 protein is one of the major enzymes involved in labeling p53protein with ubiquitin. As a celular response to DNA damage,oncogenic stress and cellular stress con-djtions, p53 is phosphorylated, rendering it unable to bind to MDM2, which in turn results in the stabili-zation of p53 protein. Phosphorylation of the N-terminus of the p53 protein does not affect its DNA-
binding activity, but affects its affinity for MDM2 and its subsequent degradation.The p63 gene uses several transcription initiation sites and extensive alternative splicing to generate a bewildering number of different mRNAs. For clarity, several alternative-splicing routes at the5' end of the gene are not indicated. Several protein domains can be distinguished;of these, the TA domains, the DB, and the 0L domain are highly homologous to the corresponding domains in p53. p63 can be ex-
pressed as two N-terminal isoforms that either contain a TA domain or lack an N-terminal domain(△N)a ful TA domain through alternate promoter usage. These two isoforms in turn can each have multipleC-termjnj as a result of alternative splicing. The capacity to transactivate gene expression at a p53-re-
sponsive target is given for each of the indicated isoforms(inactive form or active form). The△N iso-forms have dominant negative(DN) effects against p53 and TAP63/p73. 
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semble full-length p53. In overexpression stud- 
ies, TAP63γwas shown to be as potent as p53 
in inducing apoptosis, whereas TAP73βis the most potent transactivating p73 isoform. How- 
ever, both TAP63αand TAP73αisoforms cause 
weaker transactivation and apoptosis than other TA isoforms, and deletion of a C-terminal SAM 
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(sterile alpha motif) domain restores the transac- tivation potency of both TAP63αand TAP73α
(Fig.1) 
It is still unclear whether and to what ex- 
tent TAP63 and TAP73 play roles in tumor sup- 
pression. p63/p73 mutations are not commonly 
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Figure 2 Specific target sequence for p53 family members. A. Nearly al p53 response elements previously reported contain two adjacent copies of the 10-bp motif. In contrast, studies in our laboratory and in others suggest that spacing between at least three copies of thole-bp motif may be important 
for p73- and p63-specific transcriptional activation. B. List of the specific target genes for p53family members, experimentaly validated by Chip and reporter assays. Left, the capacity to transactivate gene expression is given for each of the members. Right, schematic representation of the binding site within the target genes. 
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observed in human tumors. However, several 
lines of evidence suggest that p63 and p73 also 
mediate celular responses to DNA damage 
agents and possess potential tumor suppression 
activity lnviv,o. When overexpressed, TAP63/p73 
can activate a number of common p53 respon- 
sive genes involved in cel cycle arrest and 
apoptosis. Additionally, in one genetic back- 
ground, mice heterozygous for p63 and p73 de- 
veloped tumors6). 
2. Target genes of p53 family members
Despite extensive studies on the biological 
functions of the p53 family,little is known about 
the specific DNA binding sequences of p63 and 
p73 or the target genes regulated specificaly by 
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p63 and p73 but not by p53 (Fig. 2A). Identify- ing the specific target genes for each member 
of the p53 family that plays a role in cel prolif- 
eration and/or development is an important 
step for better understanding the physiological 
and tumor-repressive roles of p53 family mem- 
bers. So far, several genes have been reported 
to be specific targets of p63 and p73, such as 
AQP3 REDD1, JAG1, JAG2, .IL4R, deltaNp73, PEDF FLOT2, and ApoD. We and other 
groups have identified several target genes spe- 
cifically regulated by p63 and p73 and their re- 
sponse elements, as summarized in Fig2B. 
Nearly all p53 response elements reported 
previously contain two adjacent copies of thole 
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Figure 3 p53 transcriptional targets in apoptosis. A. The activation of p53 is induced by a variety of cell stresses, such as DNA damage,oncogene activation, spindle damage and hypoxia. Activated p53 transactivates a 
number of genes, many of which are involved in DNA repair, cel cycle arrest and apoptosis. Induction of p53 apoptotic targets can promote apoptosis.0n the other hand, the cell cycle arrest mediated by cel cycle inhibitors like p21 can inhibit the apoptotic response. The suppression of these cell cycle inhibitors leads to the preferential induction of apoptosis rather than cel cycle arrest folowing p53 activation. B.
Synergistic efect of p53 and miRNAs on cancer therapy. p53 gene transfer does not always have a good therapeutic outcome. To explore the potential for a cancer therapy strategy that reintroduces p53while inhibiting p21, we designed a recombinant adenovirus that includes p53 and microRNAs targeting 
p21. This vector expresses p53 while knocking-down p21. Introduction of this vector resulted in apopto-sis in cancer cels and reduced tumor volume in a xenograft model more successfully than p53 alone.This result demonstrates the synergistic effect of p53 and miRNAs that target apoptosis inhibitory genes, and points the way to a novel approach for overcoming resistance to p53 gene therapy. 
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-bp p53-binding motif7), whereas studies in our laboratory and in others of the response ele- 
ments for p73 and p63 within the AQP3 JAG1, 
JAG2 n -4Rα, PEDF, FLOT2 APOD, and TNNI2 genes and the p73 gene itself show 
that these elements consist of three or four cop- 
ies of the 10-bp consensus p53-binding motif 
separated by spacer sequences of up to 8-bp 
(Fig 2A). We demonstrated that the spacer nu- cleotides in a response element of the IL-4R al- 
pha (IL-4R()c) gene enhance p73-specific trans- activation of IL-4Rα8), suggesting that a spacer 
of at least three copies of thole-bp motif may 
be important for p73- and p63-specific tran- scriptional activation. 
(l) JAGl and JAG2To investigate how p63 and p73 are in-
volved in tumorigenesis and normal develop- 
ment, we attempted to identify target genes 
that are specificaly regulated by p63 and/or 
p73 but not by p53. We found that the Jagged1 (JAG1) and Jlagged2 (JAG2) genes, which en- code ligands for the Notch receptors, are up- 
regulated by p63 and p739). In addition, we iden- 
tified p63-binding sites in the second intron of 
bothJAG1 and JAG2 genes, which can directly interact with p63 protein in cels, as assessed by 
a chromatin immunoprecipitation assay. Our 
findings show an association between the p53 
family genes and Notch signaling, and suggest a 
potential molecular mechanism for the involve- 
ment of the p53 family genes in normal devel- 
opment. 
(2) IL-4Rαp73 plays important roles in neurogenesis, 
sensory pathways, and homeostatic regulation. 
We found that the IL-4Rαgene is up-regulated 
by p73 but not significantly by p53 in several human cancer cell lines8). In addition, we identi- 
fied a p73-binding site in the first intron of the 
IL-4R()t gene that directly interacts with the 
p73 protein in cells. This p73-binding site con- 
sists of eight copies of ale-bp consensus p53- 
binding motif and is a functional response ele- 
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mont that is relatively specific for p73 and p63 
among p53 family members. We also found that 
p7313-transfected tumor cells are sensitive to IL 
-4-mediated apoptosis. Our data suggest that 
IL-4Rαcould mediate, in part, certain immune 
responses and p73-dependent cell death. 
(3) PEDF
We discovered that expression of pigment 
epithelium-derived factor (PEDF) was specifi- cally induced by either p63 or p73, but not by 
p53'°). We also found that thePEDF gene con- 
tains a response element specific for p63 and 
p73 proteins in its promoter region and is a di- 
rect target of p63 and p73. Additionally, PEDF 
acts as a natural angiogenesis inhibitor in two 
hormone-sensitive organs, prostate and pan- 
creas. Together, p63 and p73 may be involved 
in cell fate by inducing PEDF expression. 
(4) FLOT2
We report here that floti1in-2 (FLOT2) a 
major hydrophobic protein localized to biomem- brane microdomainlipid rafts, is a direct tran- 
scriptional target of members of the p53 fam- 
ily''). Such rafts have been suggested to play an 
important role in many cellular processes, in- 
cluding signal transduction, membrane traffick- 
ing, cytoskeleta1organization, and pathogen en- 
try. We found that the expression of floti1in-2 
was specificaly up-regulated by either TAP73βor TAP63γ, but not significantly by p53. Fur- 
thermore, we identified a conserved p73/p63- 
binding site located upstream of the flot111in-2 
gene that is responsive to p53 family members. 
W e also found, by assessing IL-6-mediated 
STAT3 phosphorylation, that ectopic expression 
of TAP73 as well as TAP63 enhances signal transduction. Thus, in addition to direct transac- 
tivation, p53 family member genes enhance a 
set of cellular processes via lipid rafts. 
(5) ApoDWe found that the expression of apoD was 
specifically up-regulated by either TAP73 or 
TAP63, but not significantly by p53'2). In addi- 
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tion, apoD transcription is activated in response 
to cisplatin in a manner dependent on endoge- 
nous p73. We also identified a p73/p63-binding 
site in the promoter of the apoD gene that is 
responsive to p53 family members. The ectopic 
expression of TAP73 as well as the addition of 
recombinant human apoD to culture medium in- duced the osteoblastic differentiation of the hu- 
man osteosarcoma cell line Saos-2, as assessed 
by alkaline phosphatase (ALP) activity. Impor- tantly, apoD knockdown abrogated p73-medi- 
ated ALP induction. These results suggest that 
apoD induction may mediate the activity of p73 
in normal development. 
3. p53 family gene therapy
Exogenous overexpression of p53 inhibits 
the growth of cancer cells by inhibiting cel cy- 
cle progression and inducing apoptosis. Loss of 
p53 not only results in the development of tu- 
p53 
p63γ
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Hybrid C 
Hybrid D 
Hybrid E 
Hybrid F 
mors, but also in chemoresistance in many 
types of cancer. Therefore, introducing wild- 
type p53 back into tumor cells results in the ac- 
tivation of growth inhibitory pathways, which 
makes tumor cells sensitive to chemotherapeu- 
tic drugs. Indeed, p53-based gene therapy has 
been shown to be very effective against several 
types of cancer. However, p53-based gene ther- apy is not effective under certain conditions. 
For example, amplification of MDM2, mutational 
inactivation of pl4ARF,or presence of the HPV 
E6 oncogene in HPV positive cervical cancer in- 
activates the p53 pathway of growth suppres- 
sion. Although p53 gene therapy is being tested 
clinically for the treatment of human cancer, 
some cancer models(in vivo and in vitro) are re- sistant to p53. To explore the potential use of 
two p53 homo1ogues, p63 and p73, in cancer 
gene therapy, we introduced p53, p63 and p73 into colorectal cancer and osteosarcoma cel 
Figure 4 p53/TAP63γhybrid constructs. We have generated a set of novel hybrid genes by taking advantage of the differential regulation of p53 and p63. The six hybrid proteins consist of three functional domains, each of which is derived from either p53 or p63. The constructs used are shown: for example, 'Hybrid A'
is a hybrid protein containing the N-terminal and central domains of p53 fused in-frame to the C-termi-nal domain of p63;'Hybrid B' is a hybrid p53 protein whose central domain is replaced with the central domain of p63. First, we expected that'Hybrids A, D and E' containing the C-terminal domain of p63
would not oligomerize with endogenous mutant p53 in cancer cels. We also expected that'Hybrids C and E' containing the N-terminal domain of p63 would neither bind to MDM2 nor be degraded in the proteasome pathway, although they stil contain the central DNA-binding domain of p53. Finally, we supposed that'Hybrids B and F' would change the transcriptional activity of p63 because the distinct C
-termini(α, l3 andγ)of TAP63 are thought to modulate the ability of the respective TA isoforms to transactivate gene expression. 
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lines via adenovira1 vectors, and compared their 
effects on cel growth. 
(l) Adenovirus-mediated transfer of p53 fam- ily genes: potential application to gene ther- 
apy of colorectal cancer and osteosarcoma
Among 10 cell lines tested, six cel lines dis-
played a similar response each other folowing 
transduction of p53, p63 or p73; two lines under- 
went cel-cycle arrest; three lines exhibited 
apoptosis; and one line showed no effect follow- 
ing transduction. The effect on cell-cycle pro- gression varied in the other four cel lines. Inter- 
estingly, three cel lines were resistant to p53- 
mediated apoptosis, including two lines with en- 
dogenous wild-type p53 aleles, but underwent 
apoptosis after transduction of p63 or p73. Simi- 
lar to p53, transduction of p63 induced extensive 
apoptosis when combined with adriamycin or X -radiation in SW480 cels, which are resistant to 
apoptosis. Transduction of p63 and p73 also re- 
duced the tumorigenicity of two colorectal can- 
cer cels in vivo. These results suggest that ade- 
novirus-mediated p63 and p73 transfer could 
represent a novel approach for the treatment of 
human cancers, particularly tumors that are re- 
sistant to p53 gene therapy'3). 
Osteosarcoma is one of the most common 
malignancies of the bone. Although prognosis of 
osteosarcoma has improved significantly during 
the past several years due to more intensive 
chemotherapy and radiotherapy regimens, new 
therapeutic approaches are needed for recur- 
rent and inoperable cases. Like p53, p63 and p73 
induce apoptosis in several cell types. W e evalu- 
ated the antitumor effects of p63 and p73 on 
eleven different human osteosarcoma cell lines'4). 
In vitro, adenovirus-mediated transduction of 
p63γinduced apoptosis in osteosarcoma cells 
that were resistant to p53-mediated apoptosis. 
Interestingly, the apoptotic effects of p63γwere greater than those of wild-type p53 in osteosar- 
coma cels with MDM2-amplification. We then 
determined the therapeutic effect in vivo of in- 
tratumora1 injection of adenovirus-vectors ex- 
39 
pressing p53 family members into xenografts 
derived from Saos-2 cels implanted in nude 
mice, and found that infection with Ad-p63γ
suppressed tumor growth more effectively than 
infection with Ad-p53. In addition, exogenous 
p73βand p63γsignificantly increased the che- mosensitivity of osteosarcoma cells to doxorubi- 
cin and cisplatin, which are commonly used as 
chemotherapeutic agents in the treatment of os- 
teosarcoma.0ur studies suggest that adenovi- 
rus-mediated transduction of p53 family mem- 
bers may be useful in gene therapy of osteosar- 
coma, particularly when they are combined 
with chemotherapeutic agents'4). 
(2) Histone deacetylase inhibitor FK228 en- hances adenovirus-mediated p53 family gene 
therapyCurrent clinical success rates of adenovira1 
vector-based gene therapy remain unsatisfac- 
tory. A major obstacle to this approach is thought to be the low adenovira1 vector trans- 
duction efficiency of tumor cels, which has been 
attributed to the weak expression of the cox- 
sackie-adenovirus receptor(CAR). Therapeutic replacement of the wild-type p53 gene has 
been pursued as a potential gene therapy strat- 
egy in a variety of cancer types; however, some 
cancer models are resistant to p53 fn vlvo and 
in vitro. Therefore, to improve p53 gene ther- 
apy, it is important to overcome the resistance 
to p53-mediated apoptosis.
Histone deacetylase inhibitors are a novel 
class of chemotherapeutic agents that reverse 
the malignant phenotype of transformed cells. 
A natural histone deacetylase inhibitor, FK228 
(also called Romidepsin/Istodax), is a member of a new class of antineoplastic agents that are ac- 
tive in T-cel lymphoma. FK228 has been ap- proved by FDA and is in clinical use for the 
treatment of cutaneous T-cell lymphomas. In 
addition, FK228 is currently in phase II clinical trials for the treatment of advanced solid tu- 
mors. FK228 has been reported to enhance ade- 
novirus infection due in part to its ability to up- 
regulate coxsackievirus adenovirus receptor ex- 
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press1on.
We performed preclinical experiments to establish a mechanistic rationale for the use of a 
combination of adenovirus-mediated p53 family 
gene transfer and FK228 pretreatment in future clinical trials'5). Pretreatment with FK228 en- 
hanced apoptosis in human cancer cels through 
enhanced transduction of Ad-p53. FK228 also 
induced hyperacetylation of the p53 protein and 
specificaly enhanced p53-mediated Noxa ex- 
pression. Additionaly, the combination of FK228 
and Ad-p53 induced Bax celular-translocation to mitochondria. The double knockdown of Bax 
and Noxa expression by smal interfering RNA 
antagonized the synergistic effect of Ad-p53 
and FK228 on apoptosis induction. In human 
cancer xenograft models, FK228 significantly in- 
creased the therapeutic effectiveness of p53 as 
wel as that of p63. These results provide a 
strong rationale for the use of a combination of 
p53 gene therapy and HDAC inhibitor pretreat- 
ment in cancer therapy. 
(3) A single recombinant adenovirus express- ing p53 and artificial microRNAs targeting 
p21
Although gene transfer involving p53 is 
viewed as a potentially effective cancer therapy, 
it does not result in an effective therapeutic re- 
sponse in all human cancers. The activation of 
p53 induces either in cell cycle arrest or apopto- 
sis(Fig 3A). Cell cycle arrest in response to p53 activation is mediated primarily through the in- 
duction of the cyclin-dependent kinase inhibitor 
p21'6). Because p21 also has an inhibitory effect 
on p53-mediated apoptosis, the suppression of 
p53-induced p21 expression would be expected 
to result in the increased induction of apoptosis. 
We developed an adenovirus vector that ex- 
presses p53 and suppresses p21 simultaneously 
to enhance p53-mediated apoptosis'7). A replica- 
tion-deficient recombinant adenovirus(Ad-p53/ 
miR-p21) was constructed, enabling co-cistronic 
expression of both p53 and artificial microRNAs 
that were designed to specifically knockdown 
the p21 gene(Fig 3B). An evaluation of thera- 
peutic e?ectiveness of this vector f'n vitro and fn vlvo showed that the levels of p21 were sig- 
nificantly attenuated following infection with Ad 
-p53/miR-p21. In colorectal and hepatocellular 
carcinoma cells, infection with Ad-p53/miR-p21 
augmented apoptosis as compared with a re- 
combinant adenovirus that expressed p53 alone 
(Ad-p53/miR-contro1). Ad-p53/miR-p21 also significantly increased the chemosensitivity of 
cancer cells to adriamycin. In a xenograft tumor 
model in nude mice, tumor volume was signifi- 
cantly decreased following the direct injection of Ad-p53/miR-p21 into the tumor, as com- 
pared with the injection of an Ad-p53/miR-con- trol. These results suggest that the simultane- 
ous adenovirus-mediated transduction of p53 
and microRNAs designed to specifically knock- 
down p21 may be useful for gene therapy of hu- 
man cancers'7)・ 
(4) Super Hybrid p53The p53 family protein consists of three 
separable and functionaly essential domains: an 
N-terminal transcriptional activation domain 
(TA), a central core sequence-specific DNA- 
binding domain (DB) and a C-terminal located 
oligomerization domain(0L)'8) (see Fig.1). How- ever, p53 and p63 show distinct patterns of 
transcriptional and post-transcriptional regula- 
tion. p53 is ubiquitously transcribed at a rela- 
tively high level, while the amount of p53 pro- 
tein in normal cells is determined mainly by the 
rate at which it is degraded. The degradation 
proceeds through proteolysis mediated essen- 
tially by the ubiquitination of p53 by MDM2. 
This process is subject to a feedback loop. Phos- phorylation of the N-terminus of p53 protein 
does not affect its DNA-binding activity, but af- 
fects its affinity for MDM2 and its subsequent 
degradation3). 
In contrast to p53, however, protein degra- 
dation does not mainly regulate the transcrip- 
tional activity of the p63. The structure of p63 is 
more complex than that of p53 due to the exis- 
tence of several p63 variant isoforms. The p63 
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gene is expressed as multiple isoforms with dif- 
ferent N-and C-termini, which results from the 
use of two different promoters and alternative 
splicing. p63 isoforms can possess one of two N- 
termini;one that is transcriptiona11y active(TA) 
and the other N-terminaly deleted(ΔN). Addi- tionaly, these isoforms can have different C-ter- 
mini(α, β, γand etc)5). The functional differences among p53 family members could be due partly 
to differential regulation of alternative promot- 
ers and splicing, as exemplified by the multiple 
splice variants of p63. △N variants lack the transactivation domain and are transcribed from 
an internal promoter within exon3of the ful- 
length gene4,'9). The different isoforms have dif- 
ferent activities; the TA isoforrns function simi- 
larly to p53 in cultured cells, transactivate some 
p53 target genes but not others, and induce 
apoptosis. In contrast, the △N isoforms are 
thought to play a role in inhibiting the transacti- 
vation of target genes of p53 and TA isoforms 
of p63. Therefore, △Np63 isoforms can exert 
dominant-negative effects over p53, TA p73, 
and TAP63. The TA isoforms might function in 
tumor suppression, while increased expression 
of the△N isoforms might be oncogenic'9). 
To enhance the tumor suppressive activity 
of the p53 family, we generated a set of novel 
hybrid genes by taking advantage of the differ- 
ential regulation of p53 and p63 activities. The 
basic constructs of the hybrid proteins are 
shown in Fig 4. The six hybrid proteins consist of three functional domains, each of which is de- 
rived from either p53 or p63. The constructs 
used our recent study (in preparation) are shown in Figure4: for example, 'Hybrid A' is a 
hybrid protein containing the N-terminal and 
central domains of p53 fused in-frame to the C- 
terminal domain of p63;'Hybrid B' is a hybrid 
p53 protein whose central domain is replaced 
with the central domain of p63. First, we ex- 
pected that'Hybrids A, D and E' containing the 
C-terminal domain of p63 would not oligomerize 
with endogenous mutant p53 in cancer cells.
We also expected that'Hybrids C and E' 
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containing the N-terminal domain of p63 would 
neither bind to MDM2 nor be degraded in the 
proteasome pathway, although they stil contain 
the central DNA-binding domain of p53. Finaly, 
we supposed that 'Hybrids B and F' would 
change the transcriptional activity of p63 be- 
cause the distinct C-termini(α, βand r)of TA p63 are thought to modulate the ability of the 
respective TA isoforms to transactivate gene 
expression. W e have tested the effects of each 
of the six hybrid constructs on tumor suppres- 
sion activity. Interestingly, significantly higher 
proapoptotic activity than that of p53 and p63 
was obtained only when one specific hybrid was 
introduced in tumor cels. Thus, this hybrid con- 
struct is a promising candidate for the 'Super 
Hybrid p53' approach to gene therapy of cancer. 
4. Conclusions
The p53 tumor-suppressor gene integrates 
numerous signals that control cell life and death. 
As when a highly connected node in the inter- 
net breaks down, the disruption of p53 function 
has severe consequences20-2). The fact that the 
p53 pathway is impaired in the majority of hu- man cancers has encouraged efforts to under- 
stand p53 function in normal and neoplastic states. Most human tumors exhibit inactivation 
of p53, either through direct mutation of p53 it- 
self,or through disruption of regulatory path- 
ways essential for p53 function. 
Functionaly, therefore, it is clear that p53-
targeted therapy could alow tumor-specific in- 
tervention. Smal molecule strategies have been 
designed to activate p53 family members such 
as p73; to manipulate p53 posttranslationa1 
modulators with the aim of increasing wild-type 
p53 protein levels; to develop protein-protein in- 
teraction inhibitors such as Nutlin-3 to prevent 
wild-type p53 binding to MDM2or viral pro- 
teins; and to restore p53 function to mutant p53 by direct modulation of its conformation. An- 
other direct method is to deliver the functional 
wild-type p53 to tumors via gene therapy.
Recently, gene therapy has shown promise 
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in preclinical studies as a novel molecular treat- 
ment for malignant tumors. Multiple gene trans- 
fer strategies that enhance immune responses, 
or introduce foreign genes that directly kill tu- 
mor cels by restoring the function of a defec- 
tive tumor-suppressor gene or by inducing 
apoptosis, are presently under investigation. 
The effective administration of therapeutic 
genes to tumor cel targets requires an efficient 
delivery system. W hile it is accepted that ade- 
novira1 vectors are superior for fn vlvo gene 
transfer, the current efficiency of gene transfer 
by these vectors may nonetheless be suboptimal 
for cancer gene therapy. In several clinical trials 
involving fn rrvo gene delivery, the resistance 
of target tissues to adenovira1 infection has been 
reported. The most promising strategy has been 
pursue the gene transfer experiments that origi- 
naly helped to establish p53 as a tumor sup- 
pressor in human cancer patients. Indeed, sev- 
eral organizations took up this approach, includ- 
ing Introgen Therapeutics (Texas), which re- ported promising data as early as l996. How- 
ever, the trials and transfer of the technology to 
the clinic were slow to complete. Eventually, 
p53, delivered with the aid of an adenovirus vec- 
tor, was approved in2004 for the treatment of 
head and neck cancer in China. Although we still have to wait for a critical assessment of the 
results of this trial, it is remarkable that this is 
the first ever gene therapy protocol approved for routine clinical use in humans. 
We previously reported that the p53 family 
members p63 and p73 have a significant apop- 
totic effect in cancer cells'3,'4). The incorporation 
of p53 family genes together with multiple, tan- 
dem artificial miRNAs targeting negative regu- 
lators of these family members in a single re- combinant adenovirus could also be effective'7). 
Our studies suggest that adenovirus-mediated 
transduction of p53 family members may have 
utility in gene therapy of human cancers, par- 
ticularly in combination with chemotherapeutic 
agents. We have also shown that a non-cyto- toxic dose of HDAC inhibitor FK228 can en- 
hance transgene expression and the therapeutic 
effect of adenovirus-mediated p53 family gene 
transfer'5). These studies suggest a simple, clini- 
caly practical method for increasing the sensi- 
tivity of cancer cells to adenovira1 gene therapy 
vectors. By avoiding the need for high adenovi- 
ra1 titers, the likelihood of viral toxicity is re- 
duced. Hence, future study should be considered 
in planning clinical trials combining adenovirus- 
mediated p53 family gene transfer and HDAC 
inhibitors'5). 
In the current study, we designed an ade- 
novira1 vector that expressed artificial p21-spe- 
cific miRNAs'7). Artificial miRNAs designed 
against negative regulators of p53 could also be 
utilized. The MDM2 oncogene is amplified in 
several cancers. However, MDM2 is a p53 tar- 
get gene that also mediates the ubiquitination 
and degradation of p53, thereby creating a 
negative-feedback mechanism for regulating 
p53 celular levels. Missense mutations of p53 
are found in many cancers and exert a domi- 
nant negative effect on exogenous wild-type 
p53. Thus,one could design artificial miRNA se- 
quences that target the 3'UTR of the p53 
mRNA, which would specifically knock down 
endogenous mutant p53, while having no effect 
on exogenous wild-type p53 expressed from an 
expression vector containing only the coding re- 
gion of p53.One would expect that if additional 
negative regulators of p53 are knocked down, 
with artificial miRNAs designed into this vector 
system, the apoptotic effect of p53 might be en- 
hanced. Vector-mediated gene transfer of p53 
is viewed as a potentially effective cancer ther- 
apy. Therefore, many clinical trials of adenovi- 
rus-mediated p53 gene therapy are ongoing. 
Our ongoing pre-clinical studies suggest that 
p53 family members and Super Hybrid p53 
gene therapy, as wel as combinations of these 
approaches with other strategies including 
HDAC inhibitors and RNAi-mediated suppres- 
sion of anti-apoptotic genes, should be explored 
as ways of overcoming cellular resistance to p53 
gene therapy in human cancers. Although most 
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of current pre-clinical gene therapy needs fur-
ther optimization, the success in proving that 
gene delivery can reactivate p53 marks the first 
step in transferring p53 family-based cancer 9. 
therapy to the clinic. 
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